Organization
Parker Institute for Cancer Immunotherapy
3 clinical trials
2 abstracts
Abstract
Use of a tissue-free epigenomic circulating tumor DNA (ctDNA) assay for quantification of tumor fraction (TF) and association with outcomes from RADIOHEAD real-world advanced pan-cancer cohort.Org: Parker Institute for Cancer Immunotherapy,
Clinical trial
A Multicenter Phase 1b Randomized, Placebo-controlled, Blinded Study to Evaluate the Safety, Tolerability and Efficacy of Microbiome Study Intervention Administration in Combination With Anti-PD-1 Therapy in Adult Patients With Unresectable or Metastatic MelanomaStatus: Completed, Estimated PCD: 2022-03-04
Clinical trial
A Multicenter, Open-Label, Exploratory Platform Study to Evaluate Biomarkers and Immunotherapy Combinations for the Treatment of Patients With Metastatic Castration-resistant Prostate CancerStatus: Completed, Estimated PCD: 2022-10-03
Clinical trial
An Exploratory Study of Nivolumab With or Without Ipilimumab According to the Percentage of Tumoral CD8 Cells in Participants With Advanced Metastatic CancerStatus: Completed, Estimated PCD: 2023-06-30
Abstract
ACHILLES TENDINITIS - US-GUIDED INTRATENDINOUS STEROID INJECTIONOrg: Parker Institute for Cancer Immunotherapy, Frederiksberg Hospital, Copenhagen, Denmark,